Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: In 2004, a virulent form of canine influenza surfaced at greyhound racing parks in Florida. In that outbreak, it infected 24 greyhounds and killed 8 more. The contagion has since been confirmed in seven states, having killed greyhounds at tracks in Florida, Massachusetts, Arizona, West Virginia, Wisconsin, Texas and Iowa. It is highly contagious, spreading through shared items (like toys) or human contact (kennel workers have carried the virus home with them), in addition to dog-to-dog encounters. The virus that has been felling greyhounds is an H3N8 flu closely related to an equine flu strain. It is not related to typical human flus or to the H5N1 avian flu that killed about 100 people in Asia. Several states including Florida, Minnesota, and Louisiana,among others reported another rash of cases in late June 2017. According to the American Veterinary Medical Association (AVMA), the outbreaks in those states were caused by a strain known as canine H3N2 influenza, which was first reported in Chicago in 2015. An AVMA spokesperson, Sharon Granskog, told us in a phone interview that such outbreaks can be seasonal in nature: There's a time of year when more dogs are in contact with one another, they're at dog parks, it's highly contagious. We suggest that you make sure if your dog is going to a dog park that it's healthy and talk to a veterinarian about whether or not a vaccine would be right for your dog. The disease was first reported in the U.S. in 2004 after several racing greyhounds in Florida contracted it. The AVMA said that they believed that the dogs became infected by a strain of H3N8 influenza, which is particular to horses. Dr. Ruben Donis, chief of molecular genetics for the influenza branch of the Centers for Disease Control and Prevention, confirmed that the flu jumped from horses to dogs, "a very rare event of considerable scientific interest" and added "at this point, there is no reason to panic." How that jump occurred is either not known at this point or is not being commented on, so the email's assertion that the eating of raw meat was to blame should be regarded as speculation rather than as fact. While there is always the possibility the virus might again jump species, this time to humans, this strain of flu has been present in horses for more than 40 years without any documented cases of humans catching it or the related canine flu. But there are vaccines available for both the equine and canine flus. Many readers have been confused (and unnecessarily frightened) by the difference between the terms "morbidity rate" and "mortality rate." The morbidity rate describes the percentage of animals that will contract the disease after being exposed to the virus, but, despite its name, the term has nothing to do with the death rate associated with the flu. (Nearly 80 percent of dogs exposed to the canine flu virus will contract only a mild form of the disease which mimics kennel cough, a type of canine bronchitis that is rarely serious.) The mortality rate, which describes the percentage of animals that will die after contracting the disease, is in the much lower range of 5 to 8 percent, according to Dr. Cynda Crawford, the veterinary immunologist who first isolated the canine flu virus: The mortality rate is around 5 to 8 percent, says veterinarian Cynda Crawford at the University of Florida's College of Veterinary Medicine in Gainesville. "I want to stress that despite the rumors that are out on the Internet and other such sources, this disease is not as deadly as people want to make it," Crawford said. She says she receives more than 30 calls a day from concerned veterinarians. Dr. Crawford describes the contagion as producing in dogs "a moist, productive cough that ends in a gagging response, that will persist for one to four weeks, despite treatment with antibiotics or cough suppressants. Some dogs develop a thick, yellow discharge from the nose. A very few dogs will spike a high fever, between 105 to 107 degrees Fahrenheit. They become lethargic and weak, with rapid, shallow breathing. This is likely to progress to pneumonia." Other veterinary experts have estimated the potential death rate as between 1 and 10 percent, with the higher percentage applying to very young, very old, or infirm dogs. Presence of the virus in dogs can be confirmed only through blood tests performed at the Cornell University College of Veterinary Medicine. Results of such blood screens take as long as two weeks. Dr. Crawford recommends keeping dogs showing symptoms of respiratory disease at home and away from other dogs for up to two weeks. The CDC, which is tracking the disease, issued no official recommendations. Because the symptoms of this as yet unnamed virus somewhat mimic bordetella, a less virulent illness commonly known as kennel cough, it is hard to ascertain how widespread the flu has become. On the flipside of that confusion, vets in various parts of the country have been thrown into a panic when encountering run-of-the-mill kennel cough in any of their clients, fearing they are instead confronting cases of the new flu. The Animal Health Diagnostic Center at Cornell University inserted a caution against such hair-trigger diagnosis within a larger advisory about the potential for the flu to have spread to the state of New York: "One should not lose sight of the fact that all respiratory infections in dogs are not due to canine influenza virus. Adhering to the 'band wagon' approach could result in the failure to appropriately treat dogs with infections previously known to cause respiratory problems in dogs." We found this good advice for vets and dog owners in our inbox one day: PLEASE DO NOT PANIC, and do NOT assume that every cough is Canine Influenza. Kennel Cough from parainfluenza and Bordetella is more common. However, the Animal Health Diagnostic Center at Cornell is interested in receiving samples from dogs that appear to have kennel cough. Clinical Signs: Since this is a new pathogen in dogs, there is currently no natural immunity present in the unexposed canine population. Almost all exposed dogs will become infected, and nearly 80% have clinical signs. In the mild form the dogs will have a cough that persists for 10 to 21 days. The cough may be soft and moist or dry. Many dogs will have a nasal discharge from a secondary bacterial infection and low grade fever. The nasal discharge responds to broad spectrum antibiotics. In the severe form with pneumonia there is a high fever (104-106 F) and respiratory difficulties. X-rays may show consolidation. These dogs often have secondary bacterial infections and have responded to broad-spectrum antibiotics and supportive care including intravenous hydration. The incubation period is two to five days and dogs may shed virus for seven to 10 days. The disease can spread rapidly throughout a boarding kennel. Dogs that are coughing SHOULD NOT BE BROUGHT TO SHOWS or Performance EVENTS. In a 1 June 2017 advisory to its members, the AVMA suggested that vaccines against the H3N2 virus strain "might be another prevention option" for dogs who were at least 8 weeks old and also recommended isolating dogs who could be infected, as well as not sharing toys between dogs and disinfecting shelter, veterinary, and boarding facilities. Claim: A virus deadly to dogs has been spreading in the canine population of the U.S.

Answer: Has a virus deadly to dogs been spreading in the canine population of the U.S.?

Question: Paragraph: Two people who had travelled from Congo died in Uganda last week, the World Health Organization said. A three-year-old boy who was sent back to Congo after testing positive for the disease died at the weekend, Congo's health ministry said. At least another 1,411 people have died in Congo since August in the second worst outbreak of the disease on record. "Happy to inform you all that we got clearance from both Uganda National Council for Science and Technology and National Drug Authority to bring in the Therapeutic treatment for #Ebola patients in the country," Uganda's Health Minister, Jane Ruth Aceng, said on Twitter. The treatments approved for shipment to Uganda were Mapp Biopharmaceutical's ZMapp, Regeneron Pharmaceuticals Inc's REGN-EB3 and Remdesivir, made by Gilead Sciences, said WHO spokesman Tarik Jasarevic. "The protocols for the fourth being submitted. Logistics underway with MSF support for importation of a few courses about 10 each," he added in an email. The U.N. health agency has said there have so far been no known cases of Ebola spreading between people in Uganda - all recorded patients had travelled in from Congo. Four experimental therapeutic treatments are already being used in Congo, it added. On Friday, a WHO panel decided not to declare an international emergency over Congo's Ebola outbreak despite its spread to Uganda, saying such a declaration could cause too much economic harm. "Obviously, the crisis is far from over," Mark Green, the head of the U.S. Agency for International Development (USAID), told a news conference in Nairobi. Health workers and people who came in contact with infected people began receiving a Merck experimental vaccine in Uganda on Saturday. (This story corrects name of drug in 5th paragraph to REGN-EB3, not Regeneron). Claim: Uganda clears three experimental Ebola treatments, watches for spread.

Answer: Health workers have got the all-clear to use three experimental Ebola treatments in Uganda, a week after the deadly disease spread over the border from Democratic Republic of Congo, authorities said on Tuesday.

Question: Paragraph: Irish-born William Campbell and Japan's Satoshi Omura won half of the prize for discovering avermectin, a derivative of which has been used to treat hundreds of millions of people with river blindness and lymphatic filariasis, or elephantiasis. China's Tu Youyou was awarded the other half of the prize for discovering artemisinin, a drug that has slashed malaria deaths and has become the mainstay of fighting the mosquito-borne disease. She is China's first Nobel laureate in medicine. Some 3.4 billion people, most of them living in poor countries, are at risk of contracting the three parasitic diseases. "These two discoveries have provided humankind with powerful new means to combat these debilitating diseases that affect hundreds of millions of people annually," the Nobel Assembly at Sweden's Karolinska Institute said. "The consequences in terms of improved human health and reduced suffering are immeasurable." Today, the medicine ivermectin, a derivative of avermectin made by Merck & Co, is used worldwide to fight roundworm parasites, while artemisinin-based drugs from firms including Novartis and Sanofi are the main weapons against malaria. Omura and Campbell made their breakthrough in fighting parasitic worms, or helminths, after studying compounds from soil bacteria. That led to the discovery of avermectin, which was then further modified into ivermectin. The treatment is so successful that river blindness and lymphatic filariasis are now on the verge of being eradicated. Omura, 80, said the real credit for the achievement should go to the ingenuity of the Streptomyces bacteria, whose naturally occurring chemicals were so effective at killing off parasites. "I really wonder if I deserve this," he said after learning he had won the prize. "I have done all my work depending on microbes and learning from them, so I think the microbes might almost deserve it more than I do." Omura is professor emeritus at Kitasato University in Japan, while Campbell is research fellow emeritus at Drew University in Madison, New Jersey. "This was the work of a team of researchers so it is by no means my work, it's our work," said Campbell, 85, who learned of his prize in a pre-dawn phone call from Reuters that woke him at his home in North Andover, Massachusetts. "In the first decade, there were 70 authors that I co-authored papers with. That gives you some idea of the number of people involved," he said. Tu, meanwhile, turned to a traditional Chinese herbal medicine in her hunt for a better malaria treatment, following the declining success of the older drugs chloroquine and quinine. She found that an extract from the plant Artemisia annua was sometimes effective but the results were inconsistent, so she went back to ancient literature, including a recipe from AD 350, in the search for clues. This eventually led to the isolation of artemisinin, a new class of anti-malaria drug, which was available in China before it reached the West. Tu, 84, has worked at the China Academy of Traditional Chinese Medicine since 1965. World Health Organization spokesman Gregory Hartl said the award of a Nobel prize for the discovery was a great tribute to the contribution of Chinese science in fighting malaria. "We now have drugs that kill these parasites very early in their life-cycle," said Juleen Zierath, chair of the Nobel Committee. "They not only kill these parasites but they stop these infections from spreading." Death rates from malaria have plunged 60 percent in the past 15 years, although the disease still kills around half a million people a year, the vast majority of them babies and young children in the poorest parts of Africa. The 8 million Swedish crowns ($960,000) medicine prize is the first of the Nobel prizes awarded each year. Prizes for achievements in science, literature and peace were first awarded in 1901 in accordance with the will of dynamite inventor and businessman Alfred Nobel. Last year, the medicine prize went to three scientists who discovered the brain's inner navigation system. Claim: Beating parasites wins three scientists Nobel prize for medicine.

Answer:
Three scientists from Japan, China and Ireland whose discoveries led to the development of potent new drugs against parasitic diseases including malaria and elephantiasis won the Nobel Prize for Medicine on Monday.